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Abstract
Increased pain sensitivity is a comorbidity associated with many clinical diseases, though
the underlying causes are poorly understood. Recently, chronic pain hypersensitivity in
rodents treated to induce chronic inflammation in peripheral tissues was linked to enhanced
tryptophan catabolism in brain mediated by indoleamine 2,3 dioxygenase (IDO). Here we
show that acute influenza A virus (IAV) and chronic murine leukemia retrovirus (MuLV)
infections, which stimulate robust IDO expression in lungs and lymphoid tissues, induced
acute or chronic pain hypersensitivity, respectively. In contrast, virus-induced pain hyper-
sensitivity did not manifest in mice lacking intact IDO1 genes. Spleen IDO activity increased
markedly as MuLV infections progressed, while IDO1 expression was not elevated signifi-
cantly in brain or spinal cord (CNS) tissues. Moreover, kynurenine (Kyn), a tryptophan
catabolite made by cells expressing IDO, incited pain hypersensitivity in uninfected IDO1-
deficient mice and Kyn potentiated pain hypersensitivity due to MuLV infection. MuLV infec-
tion stimulated selective IDO expression by a discreet population of spleen cells expressing
both B cell (CD19) and dendritic cell (CD11c) markers (CD19+ DCs). CD19+ DCs were
more susceptible to MuLV infection than B cells or conventional (CD19neg) DCs, proliferated
faster than B cells from early stages of MuLV infection and exhibited mature antigen pre-
senting cell (APC) phenotypes, unlike conventional (CD19neg) DCs. Moreover, interactions
with CD4 T cells were necessary to sustain functional IDO expression by CD19+ DCs in
vitro and in vivo. Splenocytes from MuLV-infected IDO1-sufficient mice induced pain hyper-
sensitivity in uninfected IDO1-deficient recipient mice, while selective in vivo depletion of
DCs alleviated pain hypersensitivity in MuLV-infected IDO1-sufficient mice and led to rapid
reduction in splenomegaly, a hallmark of MuLV immune pathogenesis. These findings
reveal critical roles for CD19+ DCs expressing IDO in host responses to MuLV infection that
enhance pain hypersensitivity and cause immune pathology. Collectively, our findings sup-
port the hypothesis elevated IDO activity in non-CNS due to virus infections causes pain
hypersensitivity mediated by Kyn. Previously unappreciated links between host immune
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responses to virus infections and pain sensitivity suggest that IDO inhibitors may alleviate
heightened pain sensitivity during infections.
Author Summary
Chronic pain is a factor in diseases that afflict many people, yet the underlying causes of
pain are poorly understood. Here we assess the effects of virus infections on pain sensitiv-
ity in mice. Infecting mice with two different viruses, influenza and mouse leukemia virus
(MuLV) increased pain sensitivity. Influenza infection caused transient increase in pain
sensitivity, which returned to normal levels after infections were cleared. However persis-
tent MuLV infections caused sustained increase in pain sensitivity. Virus-induced pain
sensitivity was reduced substantially in mice lacking the enzyme indoleamine 2,3 dioxy-
genase (IDO), which degrades the amino acid tryptophan. Moreover a natural compound
produced by cells expressing IDO enhanced pain sensitivity when administered to mice
lacking IDO genes. Thus cells expressing IDO caused increased pain sensitivity in infected
mice. A distinctive cell type expressed IDO selectively and accumulated in spleens of
MuLV-infected mice. Transfer of spleen cells fromMuLV-infected mice caused increased
pain sensitivity in uninfected mice while eliminating specific cells in MuLV-infected mice
abolished enhanced pain sensitivity. Our findings show that host immune responses to
virus infections cause increased pain sensitivity and suggest novel ways to alleviate pain
during infections.
Introduction
Enhanced pain sensitivity is a hallmark of inflammation and is a debilitating feature of many
clinical diseases, including chronic Human Immunodeficiency Virus-1 (HIV-1) infections [1,
2]. However the underlying causes of chronic pain remain poorly defined [3]. Pain hypersensi-
tivity in rats with inflamed joints correlated with elevated IDO expression in brain, and pain
hypersensitivity induced following treatments to induce chronic inflammation did not mani-
fest in mice lacking intact IDO1 genes [4]. These findings were interpreted as evidence that sus-
tained inflammation in tissues outside the central nervous system (CNS) induced IDO activity
in brain that was the underlying cause of pain hypersensitivity. However, it is not known how
local inflammation in peripheral (non-CNS) tissues induces IDO expression in brain, nor is it
clear if IDO mediates pain hypersensitivity in other inflammatory syndromes.
We tested the hypothesis that virus infections enhance pain sensitivity by stimulating IDO
using murine models of acute or chronic virus infection in which IDO enzyme activity is ele-
vated. Acute influenza A virus (IAV) infection stimulates robust increase in lung IDO activity
which wanes after virus clearance [5]. Murine Leukemia retrovirus (MuLV, LP-BM5 strain) is
a natural mouse pathogen that causes persistent infections and pathologies that resemble
aspects of human immunodeficiency virus-1 (HIV-1) infections, including sustained IDO
activity in lymphoid tissues [6–8]. The role of IDO in MuLV pathogenesis is controversial. A
previous study indicated that genetic and pharmacologic IDO ablation led to enhanced inter-
feron type 1 production and increased resistance to MuLV infection [6]. In contrast, a later
report found no differences in viral loads and immune pathologies between IDO-sufficient
(WT) mice and mice lacking intact IDO1 genes [7]. As MuLV infection also induces peripheral
neuropathy and pain hypersensitivity [9, 10] we hypothesized that induced host IDO activity
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mediates pain hypersensitivity during MuLV infection. We show that IAV and MuLV infec-
tions increased pain hypersensitivity via an IDO-dependent mechanism and that a distinctive
splenic DC subset expressing the B cell marker CD19 enhanced pain sensitivity in MuLV-
infected mice.
Results
Acute influenza A infection (IAV) incites pain hypersensitivity by inducing
IDO
IAV respiratory infections in mice stimulate IDO enzyme activity in lungs and lung-draining
(mediastinal) lymph nodes [5]. To test if IAV infection incited pain hypersensitivity we
assessed mechanical nociception (pain) thresholds by applying mechanical stimuli (von Frey
filaments) of increasing force to hind paws until mice responded as described inMethods. As
soon as one day post infection (dpi) paw withdrawal thresholds (PWT) were reduced signifi-
cantly, relative to baseline thresholds in the same mice before infection (Fig 1A). Increased
pain sensitivity persisted during IAV infection and returned to basal levels 2–3 days after IAV
clearance at 7-8dpi [5]. In contrast, no significant change in pain sensitivity manifested during
IAV infections in IDO1-deficient (IDO1-KO) mice (Fig 1A). Thus IDO1 genes were necessary
to incite pain hypersensitivity during respiratory IAV infections.
Chronic MuLV infection enhances pain sensitivity by inducing IDO in
spleen
MuLV (LP-BM5 strain) causes persistent infections and progressive pathologies, including
polyneuropathy and pain hypersensitivity [9–11]. Some features of MuLV infections resemble
aspects of clinical HIV-1 infections, including elevated IDO activity in lymphoid tissues [6, 7,
12]. Consistent with previous studies [9, 10], MuLV-infection in B6 (WT) mice bred locally
caused progressive increase in pain sensitivity until 18dpi, and levels remained elevated there-
after (Fig 1B and S1A Fig). Increased pain sensitivity also manifested in B6 mice purchased
from a commercial supplier (Taconic), though pain sensitivity was slightly less severe and took
longer to develop, relative to outcomes in B6 mice bred locally (S1B Fig). Pain sensitivity
increased in MuLV-infected IDO1-KO mice relative to naïve mice (Fig 1B and S1B Fig),
though responses in IDO1-KO mice were significantly less intense than pain hypersensitivity
induced in WTmice. Profound reduction in MuLV-induced pain hypersensitivity did not cor-
relate with major changes in virus titers or host immunopathogenesis (splenomegaly, immuno-
suppression, cytokine induction) since these parameters were comparable in WT and
IDO1-KO mice (S1C–S1F Fig), as reported previously [7]. Thus transient and sustained
increase in pain sensitivity manifested during acute IAV or chronic MuLV infections, respec-
tively, and these responses to virus infection depended on IDO1 gene expression but were not
linked to changes in virus infection kinetics or host immunopathogenesis.
To test if pharmacologic IDO inhibition alleviated pain hypersensitivity the IDO inhibitor
1-methyl-[D]-tryptophan (D-1MT, 2mg/ml) was administered continuously in drinking water
to B6 mice with established MuLV infections (60dpi). Oral D-1MT treatment for 20 days led to
significant reduction in pain sensitivity, relative to controls given vehicle only (Fig 1C). It is
unclear why oral D-1MT treatment did not alleviate pain hypersensitivity more robustly. As
spleen IDO activity increased markedly during MuLV infections (Fig 1E) D-1MT may reduce
but not abolish spleen IDO activity in this model, though potential off-target effects of D-1MT
cannot be excluded. Exposing naïve and MuLV-infected IDO1-KO mice to the natural trypto-
phan catabolite kynurenine (Kyn, 200μg/mouse, i/v) led to rapid increase in pain sensitivity;
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this effect was more severe in MuLV-infected than in uninfected (naïve) IDO1-KO mice (Fig
2D), suggesting that Kyn may synergize with cytokines co-induced by MuLV infection to
enhance pain sensitivity. Thus cells expressing IDO1 cause pain hypersensitivity in MuLV-
infected mice and Kyn released by cells expressing IDO may mediate this response. Consistent
with a previous study [6], spleen IDO activity increased progressively during MuLV infection
until IDO activity was>100-fold higher at 120dpi (Fig 1E). However IDO activity was unde-
tectable in spleens of MuLV-infected IDO1-KO mice (Fig 1E), indicating that IDO1 genes
exclusively encoded MuLV-induced IDO enzyme activity, not IDO2 and tryptophan dioxygen-
ase (TDO) genes encoding enzymes with similar functions. In contrast, at early or late stages of
Fig 1. Virus infection enhances pain sensitivity by inducing IDO. A. WT (B6) or IDO1KOmice were
infected with IAV and the paw withdrawal threshold (PWT) was assessed in infected mice using von Frey
filaments at the times indicated post infection (dpi). B. WT or IDO1KOmice were infected with MuLV
(LP-BM5, i/v) and PWT was assessed.C. As in B, except that MuLV-infectedWTmice (42dpi) were given
drinking water containing D-1MT (2mg/ml) or vehicle. D. As in B, except that uninfected (naïve) or MuLV-
infected IDO1KOmice were treated with Kyn (200μg. i/v). E. IDO activity, expressed as Kyn generated ex
vivo by homogenized spleen, fromMuLV-infectedWT and IDO1-KOmice was assessed at the infection
times indicated. F. IDO activity in brain and spinal cord tissues from naïve and MuLV-infected WTmice
(56dpi). E. F. All experiments were performed twice or more and statistical significance was assessed by
2-way ANOVA with multiple comparison (A-D) or Student’s t test (E, F); ****p<0.0001, ***p<0.001,
**p<0.01.
doi:10.1371/journal.ppat.1005615.g001
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MuLV-infection IDO enzyme activity (Fig 1F) and IDO1 gene transcription in CNS tissues
(S2B Fig) were not elevated significantly over basal levels.
MuLV infection induces a discrete population of dendritic cells to express
IDO
To identify cells expressing IDO and MuLV (GAG) genes discrete cell populations were puri-
fied by flow cytometry from spleens of MuLV-infected B6 mice and gene transcription was
assessed using quantitative RT-PCR. Splenocytes were stained with CD11c and CD19 mAbs
since melanoma growth and other inflammatory insults induce selective IDO expression by a
discrete subset of dendritic cells (DCs) expressing the B cell marker CD19 [13–16]. At early
(28dpi, Fig 2A) and later (56dpi, Fig 2B) stages in MuLV infection when immune pathology
partially or fully manifests IDO1 transcripts were detected exclusively in sorted spleen cells
expressing CD11c and CD19 (CD19+ DCs). Increased IDO1 transcription was not detected in
Fig 2. MuLV infection induces selective IDO expression by cells co-expressing DC and B cell
markers. AB. Splenocytes fromMuLV-infected B6 mice at early (A, 28dpi) or later stages (B, 56dpi) of MuLV
infection were stained with anti-CD11c and anti-CD19 mAbs, FACS-sorted to select cell populations and
RNA prepared for qPCR analyses to detect IDO1, GAGEco or GAGDef transcripts. C. FACS-sorted CD19+ or
CD19neg DCs (closed or open symbols) fromMuLV-infected Act-mOVA transgenic mice were cultured with
splenocytes from OT1 or OT2 TCR transgenic mice as indicated. After 72hrs, media was analyzed by HPLC
to detect Kyn. Statistical significance was evaluated by ANOVA or Student’s t test; ****p<0.0001.DE. Anti-
CD4 antibody was used to deplete CD4+ T cells (28dpi). Spleen IDO enzyme activity (D) and IDO1
transcription (E) were assessed 5 days later by measuring Kyn release and by qPCR. PCR analyses of
sorted splenocytes were performed once per time point, coculture experiments were performed 3 times (C),
and CD4 depletion experiments were performed twice.
doi:10.1371/journal.ppat.1005615.g002
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any other spleen cells, including sorted B cells and conventional (CD19neg) DCs. At early times
in MuLV infection (28dpi), ecotropic helper (GAGEco) and pathogenic (GAGDef) MuLV retro-
virus genes were transcribed at high levels in sorted cells expressing neither CD19 or CD11c
(CD11cnegCD19neg) and to lesser extents in CD19+ DCs, relative to sorted conventional DCs
and B cells (Fig 2A). At later stages in infection (56dpi), GAGDef transcription was still rela-
tively high in CD11cnegCD19neg and CD19+ DCs, though GAGEco transcription was relatively
high in conventional and CD19+ DCs but not in CD11cnegCD19neg cells (Fig 2B). However,
GAGDef and GAGEco transcription remained relatively low in B cells (CD19+CD11cneg) at later
stages of MuLV. Given previous reports of B cell-specific LP-BM5 expression [17], these find-
ings suggest that LP-BM5 replicates in cells not expressing CD19 or CD11c and in DCs, as well
as in B cells. Alternatively, co-selection of (or contamination by) DCs expressing CD19 may
explain previous reports of selective MuLV infection in B cells since CD19 and CD11c are com-
monly used to discriminate between B cells and DCs. Thus CD19+ DCs were highly susceptible
to MuLV infection and were the only spleen cells induced to express IDO1 during MuLV
infection.
To test if increased IDO1 transcription by CD19+ DCs led to increased IDO enzyme activity
FACS-sorted CD19+ and conventional (CD19neg) DCs fromMuLV-infected Act-mOVA trans-
genic mice expressing ovalbumin (OVA) in all cells [18] were cultured alone or with spleno-
cytes from (OVA)-specific OT1 (CD8) or OT2 (CD4) TCR transgenic mice and Kyn
production was assessed after 3 days. Kyn levels increased significantly in cultures containing
sorted CD19+ DCs and OT-2 T cells but Kyn was not detected in cultures containing sorted
DCs alone, or sorted DCs cultured with OT-1 T cells (Fig 2C). Thus interactions with OT2 T
cells were essential for IDO activity to manifest in CD19+ DCs from MuLV-infected mice.
Consistent with these findings, anti-CD4 mAb treatments to deplete CD4 cells in vivo reduced
IDO activity (Fig 2D) and IDO1 transcription (Fig 2E) in spleen to basal levels observed in
naïve mice. Collectively, these data show that interactions with CD4 T cells is essential for
CD19+ DCs to express functional IDO in MuLV-infected mice and during culture.
MuLV infection stimulates DC proliferation and selective maturation of
CD19+ DCs
CD19+ DCs are a minor DC population in spleens of naïve mice (Fig 3A,<1% of splenocytes
and ~10% of splenic DCs). CD19+ DCs expanded substantially after MuLV infection, account-
ing for ~10% of splenocytes and ~50% of splenic DCs at 35dpi (Fig 3B and 3C). Because MuLV
infection induces splenomegaly absolute numbers of CD19+ DCs expanded >100-fold relative
to numbers in spleens of naïve mice. Conventional (CD19neg) DCs also expanded in this
period, while relative proportions of splenic B cells were reduced substantially (Fig 3A and 3B).
Phenotypic analyses revealed striking differences in maturation between CD19+ DCs and con-
ventional DCs in MuLV-infected mice. At 35dpi, CD19+ DCs expressed uniformly high levels
of MHC class II (MHC II) and CD80 (Fig 3D) characteristic of mature antigen presenting cells
(APCs). In contrast, conventional DCs expressed lower and more variable levels of MHC II
and CD80/86 (Fig 3D) comparable with levels on immature DCs in naïve mice. Thus CD19+
DCs expanded and matured as APCs while conventional DCs also expanded but remained
immature during MuLV infection. Higher proportions of splenic DCs stabilized ~28dpi after
MuLV infection and in vivo labeling with 5-ethynyl-2-deoxyuridine (EdU) at 14-21dpi
revealed larger cohorts of dividing (EdU+) splenic CD19+ (~30%) and conventional (~16%)
DCs than B cells (<5%) fromMuLV-infected B6 mice (Fig 3E and 3F). In vivo treatment with
depleting anti-CD4 mAbs reduced EdU incorporation by CD19+ and conventional DCs signifi-
cantly (S3 Fig). Thus MuLV infection induced selective CD19+ DC maturation and DC
Virus Infections Induce Pain via IDO
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proliferation, as well as selective IDO expression by CD19+ DCs dependent on interactions
with CD4 T cells.
Splenic dendritic cells mediate pain hypersensitivity in MuLV-infected
mice
We tested if adoptive transfer of splenocytes from B6 mice with fully established MuLV infec-
tions (56-70dpi) enhanced pain hypersensitivity in naïve IDO1-KO recipients. Recipients were
sublethally irradiated (3.5Gy) to facilitate donor cell chimerism and six days after transfer of
splenocytes from MuLV-infected B6 (WT) donors pain sensitivity was assessed in IDO1-KO
recipients. Adoptive transfer of splenocytes fromMuLV-infected WT donors caused pain
hypersensitivity (Fig 4A), which was sustained until experimental endpoints 32 days after
transfer. Splenocyte induced pain hypersensitivity was only slightly less than pain hypersensi-
tivity due to MuLV-infection (Fig 1B). Though splenocytes fromMuLV-infected IDO1-KO
Fig 3. MuLV infection induces selective accumulation, proliferation andmaturation of CD19+ DCs in
spleen. AB. Spleens from uninfected (A) and MuLV-infected (B, 28dpi) B6 mice were stained with anti-CD19
and anti-CD11c mAbs and analyzed by flow cytometry. Numbers indicate the percentages of total cells
analyzed in each quadrant.C. Proportions of CD19+ and CD19neg DCs (gated as shown in panel B)
expressing CD19 in uninfected (naïve) and MuLV-infected mice. D. Flow cytometric analyses of MHCII and
CD80 expression by gated CD19+ DCs (red lines) and CD19neg DCs (black lines) fromMuLV-infected B6
mice (35dpi); markers highlight cells expressing high levels of MHCII or CD80. E. Representative FACS plot
of proliferating cells in spleens of MuLV infected mice labeled in vivo. EdU was injected into MuLV-infected
mice (14-21dpi) and spleen cells were analyzed by flow cytometry to detect EdU in gated B cells and DCs
4hrs later. The gating strategy used (dot plot) and markers highlighting EdU-labeled cells are shown for
MuLV-infected and naïve (control) B6 mice (light and dark gray histograms, respectively). F. Proportions of
proliferating cells (EdU+) in CD19+ and CD19neg DC populations (gated as in panel E). Statistical significance
was evaluated by Student’s t test; **p<0.01. FACS data are representative of 3 or more experiments.
doi:10.1371/journal.ppat.1005615.g003
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donors also induced significant increase in pain sensitivity (Fig 4A) these responses were signif-
icantly less pronounced than responses to splenocytes fromMuLV-infected WT donors; more-
over, sublethal irradiation may drive some increase in pain sensitivity. Thus IDO was the
major driver of pain sensitivity following splenocyte transfer.
To complement this approach, we tested if in vivoDC ablation alleviated pain hypersensitiv-
ity using transgenic B6 mice expressing human diphtheria toxin receptor (DTR) under control
of DC-specific CD11c gene promoters (CD11cDTR mice). MuLV-infected CD11cDTR mice (56-
70dpi) were treated with diphtheria toxin (DT, 10ug/kg, i/p, x2) to ablate DCs and pain thresh-
olds were monitored. DT treatment reduced pain sensitivity rapidly and significantly in
MuLV-infected CD11cDTR mice relative to MuLV-infected CD11cDTR mice not exposed to DT
and to control naïve WT mice given DT (Fig 4B). As expected, at experimental endpoints (6
days post DT treatment) the proportions of splenic CD19+ DCs were reduced significantly in
DT-treated, MuLV-infected CD11cDTR mice but DT treatment had no effects on CD19+ DCs
in MuLV-infected WT (B6) mice (Fig 4C). DT treatment also reduced spleen IDO enzyme
activity (Fig 4D) and IDO1 gene transcription (Fig 4F) in MuLV-infected CD11cDTR mice sig-
nificantly, as levels were comparable to basal levels in naïve (uninfected) mice 6 days after DT
treatment. Remarkably, spleen weights were also reduced rapidly and significantly following
DT treatment (Fig 4E). In contrast, DT treatment had no significant effects on IDO activity,
IDO1 transcription or splenomegaly in MuLV-infected WT (B6) mice (Fig 4D–4F), indicating
Fig 4. Splenic DCsmediate pain hypersensitivity during MuLV infection. A. Naïve IDO1KOmice were
exposed to sub-lethal ionizing radiation (3.5Gy) and inoculated with splenocytes (2x107, i/v) fromMuLV-
infectedWT or IDO1KO donor mice 2hrs later. Mechanical nociception (PWT) was evaluated as indicated.B.
MuLV-infected CD11cDTR mice (56-70dpi) were treated with diphtheria toxin (DT, 100ng on days 0, +2) to
deplete DCs and PWTwas evaluated. Other CD11cDTR mice were not treated with DT and MuLV-infected
WTmice were treated with DT as controls.C-F. Analyses of spleen CD19+ DCs (C), IDO activity and IDO1
transcription (D and F respectively) and spleen weights (E) in MuLV-infected CD11cDTR mice treated with DT
or vehicle (C-F) and in naïve (uninfected) B6 (WT) mice (F). Statistical significance was evaluated using
ANOVA or Student’s t test; ****p<0.0001, ***p<0.001, **p<0.01. Experiments were performed 2 or more
times.
doi:10.1371/journal.ppat.1005615.g004
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that the effects of DT treatment were due to ablation of cells expressing DTR. Thus in vivo
depletion of splenic DCs alleviated pain hypersensitivity in MuLV-infected IDO-sufficient
mice and this response was not caused by DT treatment per se. Collectively, these data reveal
that splenic DCs expressing IDO mediate sustained pain hypersensitivity in MuLV-infected B6
mice.
Discussion
IDO1 mediated pain and depression in rodents with chronic limb joint inflammation and ele-
vated IDO1 expression in brain hippocampus correlated with these responses [4]. Using the
spared nerve injury (SNI) model, Zhou et al. reported that IDO1 expressed in liver mediated
depression but did not enhance mechanical pain sensitivity in this model [19]. In the current
study we show that acute influenza (IAV) and chronic retroviral (MuLV) infections enhanced
mechanical pain sensitivity and that IDO1 ablation alleviated these responses to virus
infection.
IAV and MuLV infections stimulate IDO activity in lungs and peripheral lymphoid tissues,
respectively. IAV infections induced rapid increase in IDO activity in lung epithelial cells and
in DCs located in lung-associated lymph nodes, and IDO activity at these sites returned to
basal levels a few days after virus clearance [5]. Pain sensitivity correlated with changed IDO
activity during and after IAV infection, consistent with a causative link between IAV-induced
IDO activity and pain sensitivity. Similarly, spleen IDO activity correlated with progressive
increase in pain sensitivity that peaked before immunopathologies associated with chronic
MuLV infections manifested fully. Pain hypersensitivity peaked faster in mice bred locally than
in previous reports [9, 10] but onset of peak pain hypersensitivity was slower and comparable
with previous studies when mice from a commercial supplier were used, suggesting that mouse
husbandry factors influence the kinetics of pain hypersensitivity induced by MuLV infection.
This point notwithstanding, IDO1 ablation alleviated pain hypersensitivity almost completely
during MuLV infection. Thus IDO activity encoded by IDO1 genes caused acute pain hyper-
sensitivity during IAV infections and was the major factor driving progressive pain hypersensi-
tivity during persistent MuLV infections. Furthermore, IDO2 and tryptophan dioxygenase
(TDO) genes encoding enzymes with identical tryptophan catabolizing activities did not com-
pensate for loss of IDO1 genes to enhance pain sensitivity during IAV or MuLV infections.
Pro-inflammatory cytokines such as IL-6, TNFα and IL-1β have been reported to enhance pain
sensitivity [20]. IDO may mediate or synergize with these effects since IDO is co-induced with
pro-inflammatory cytokines in many settings of inflammation because interferons are potent
IDO inducers. However, IDO1 ablation was sufficient to block induction of pain hypersensitiv-
ity during IAV and MuLV infections, which stimulate production pro-inflammatory cytokine
responses.
CD19+ DCs were the only cell type induced to express IDO in spleen during MuLV infec-
tions and IDO1 expression and enzyme activity were not elevated above basal levels (in naïve
mice) in CNS tissues from mice with established MuLV infections. These findings suggested
that sustained IDO activity in peripheral lymphoid tissues was sufficient to incite pain hyper-
sensitivity in MuLV-infected mice. Consistent with this interpretation, adoptive transfer of
splenocytes from MuLV-infected IDO1-sufficient mice caused pain hypersensitivity in IDO1-
deficient recipients, while selective DC depletion in vivo alleviated pain hypersensitivity in
MuLV-infected IDO1-sufficient mice. While the possibility that IAV and MuLV infections
induce IDO activity in CNS tissues to incite pain sensitivity cannot be excluded fully, our find-
ings that splenic DCs fromMuLV-infected IDO1-sufficient mice and Kyn enhanced pain sen-
sitivity in IDO1-deficient mice suggest that increased IDO activity in peripheral tissues is
Virus Infections Induce Pain via IDO
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sufficient to enhance pain sensitivity. Cells expressing IDO may activate local sensory neurons
in peripheral tissues directly or Kyn produced by IDO-expressing cells may act on peripheral
or CNS neurons to enhance pain sensitivity. Collectively, our findings support the hypothesis
that sustained IDO expression by cells in lungs and splenic CD19+ DCs of mice infected with
IAV and MuLV, respectively, mediate pain hypersensitivity during infection.
Previously, we reported that splenic CD19+ DCs expressed IDO in response to melanoma
growth and inflammatory insults that induce interferon type I production, including B7 and
TLR9 ligands, DNA nanoparticles and apoptotic cells [13–16, 21, 22]. Moreover, CD19+ DCs
resemble ‘age-associated B cells (ABCs)’ that accumulate in spleens of aged female mice, in
Nba2 mice prone to lupus-like syndromes, and in patients with rheumatoid arthritis [23, 24].
ABC accumulation in aged female mice was TLR7-dependent, suggesting that endogenous ret-
roviral RNA sensing may promote ABC expansion. Similar considerations may explain why
CD19+ DCs expanded as mature APCs and expressed IDO selectively during MuLV infection.
CD19+ DCs exhibited potent T cell regulatory phenotypes dependent on IDO and interactions
between CD4 T cells and DCs were essential to sustain IDO activity in DCs and to promote
Foxp3-lineage regulatory CD4 T cell (Treg) differentiation and activation [25, 26]. Likewise,
interactions between CD4 T cells and CD19+ DCs were necessary to sustain IDO activity in
CD19+ DCs fromMuLV-infected mice. It is unclear if MuLV antigen-specific interactions
between CD19+ DCs and CD4 T cells induce IDO activity early in MuLV infection and if these
interactions promote Treg differentiation and activation. However exogenous antigens were
not required to induce splenic CD19+ DCs to express IDO following systemic B7 or TLR9
ligands and DNA nanoparticle treatments [13–15], suggesting that self antigens or antigen-
independent pathways induced CD19+ DCs to express IDO and activate Tregs in vivo. For
example, CD4 T cells may produce IFNγ or stimulate innate immune cells to express IFNαβ to
induce IDO during MuLV infection. Previously, critical roles for B cells and CD4 T cells in
MuLV-induced immune pathogenesis were described [27, 28]. Our findings suggest that
CD19+ DCs, not conventional B cells, play key roles in MuLV pathogenesis. CD19+ DCs are
closely related to B cells and express many B cell markers but are a distinct cell lineage with DC
attributes [21]. During MuLV-infection CD19+ DCs were distinguished from conventional B
cells by exhibiting mature APC phenotypes, higher susceptibility to MuLV infection, enhanced
proliferation and IDO expression dependent on CD4 T cell interactions.
A previous report described that IDO ablation led to increased plasmacytoid DCs and inter-
feron type I production in response to MuLV infection and to enhanced survival of mice
infected with MuLV alone or with MuLV and Toxoplasma gondii [6]. In contrast, we found no
significant effects of genetic or pharmacologic IDO ablation on the course of MuLV infection
or immunopathogenesis, consistent with a previous study by O’Connor and Green using
IDO1-KO mice, which also revealed that IDO is not critical, or has a redundant role in regulat-
ing host immune responses to MuLV infection [7]. The reason for these disparate outcomes is
unclear. Nevertheless, DC depletion led to rapid reduction in splenomegaly, suggesting that
DCs may play pivotal and previously unappreciated roles in immunopathologies associated
with chronic MuLV infection. However IDO ablation also had little impact on the course of
acute IAV infections in mice, though primary CD8 responses were more robust and IAV-spe-
cific memory CD8 T cell repertoires differed in the absence of IDO [5]. IDO activity is also ele-
vated in patients with persistent HIV-1 or HTLV1 retrovirus infections, indicating that
increased IDO activity is a common response to retroviral infection in mice and humans [12,
29]. It is unclear if IDO contributes to virus control or immunopathogenesis in these clinical
syndromes, though previous reports have described human pDC subsets that can express IDO
and acquire T cell regulatory phenotypes as a consequence [30, 31]. Despite the lack of evi-
dence supporting a role for IDO in host-virus immune control and immunopathogenesis, the
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current study reveals that IDO is a major contributory factor driving pain hypersensitivity dur-
ing acute IAV and chronic MuLV infections. Thus sustained, elevated IDO activity may also
contribute to chronic pain associated with acute and persistent clinical infections in humans. If
so, inhibition of IDO may help alleviate heightened pain sensitivity induced as a common
comorbidity associated with virus infections.
The mechanism by which cells induced to express IDO enhance pain sensitivity during IAV
and MuLV infections is unclear. A previous study by Kim and colleagues concluded that
increased brain IDO activity mediated pain hypersensitivity in rodent models of experimen-
tally induced arthritis [4]. This conclusion was based on findings that microinjecting IDO
inhibitor directly into rat brain hippocampus abolished pain hypersensitivity, while microin-
jecting IL-6 stimulated brain IDO expression in this rodent arthritis model. Findings from the
current study suggest that elevated brain IDO activity may not be necessary to induce pain
hypersensitivity during IAV and MuLV infections in mice since lung and lymphoid tissues
were the primary sites of elevated IDO activity during IAV and MuLV infections, respectively.
Furthermore, increased IDO expression and activity was not detected in CNS tissues of MuLV-
infected mice and adoptive transfer of splenocytes from IDO1-sufficient mice with chronic
MuLV infections or injection of Kyn heightened pain sensitivity in IDO1-deficient mice. Thus
elevated IDO activity in non-CNS tissues was necessary and sufficient to induce pain hypersen-
sitivity during IAV and MuLV infections. It is also unclear how increased IDO activity in lungs
or lymphoid tissues leads to elevated sensitivity to mechanical stimulation in hind paws.
Though unlikely that limb extremities are impacted directly by IAV and MuLV infection,
inflammatory cells expressing IDO or Kyn produced by distal tissues may enter limb extremi-
ties or CNS tissues during viral infections and heighten pain sensitivity via direct affects on
local nervous tissues.
How increased IDO activity mediates increased pain sensitivity is not understood. IDO
catabolizes both serotonin and its precursor tryptophan to generate neuroactive quinolinic
(QA) and kynurenic (KA) acids, which mediate diametric neuropathologic and neurodegener-
ative effects via N-methyl-D-aspartate (NMDA) receptors expressed by neuronal tissues to
induce pain and behavioral responses [32]. Unlike QA and KA, which can only cross the blood
brain barrier via passive diffusion, Kyn is transported efficiently across the blood brain barrier
via large neutral amino acid L-system transporters [33], and may be converted QA and KA to
drive neurological responses that enhance pain sensitivity via NMDA receptors expressed in
the CNS. Alternatively Kyn generated in non-CNS tissues during IAV or MuLV infections
may be converted to QA and KA in non-CNS tissues to promote peripheral neuropathies that
heighten pain sensitivity. Kyn is also a weak ligand for aryl hydrocarbon receptors (AhR)
expressed by multiple cell types in CNS and non-CNS tissues and modulation of AhR signaling
during IAV and MuLV infections may also contribute to peripheral neuropathies that drive
increased pain sensitivity. Thus Kyn generated by IDO activity anywhere in the body may
potentiate pain sensitivity by interactions of Kyn catabolites with nerve cells in CNS or non-
CNS tissues. Interestingly, muscular exercise reduced stress-induced depression by promoting
Kyn uptake and catabolism into KA by muscle tissues, thus decreasing the potential of Kyn
and its catabolites to cause neurologic effects [34]. This finding suggests that muscular exercise
may also to alleviate pain hypersensitivity during infections by reducing Kyn availability.
In summary, acute IAV and chronic MuLV virus infections enhanced pain sensitivity by
elevating IDO activity to increase Kyn availability. Links between host inflammatory responses
to infection, elevated tryptophan catabolism and increased pain sensitivity suggest that the
common co-morbidities of pain and behavioral disorders associated with many progressive
inflammatory diseases of clinical significance may arise due to under-appreciated metabolic
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responses to inflammatory insults such as tumor growth and autoimmunity, as well as
infections.
Materials and Methods
Mice
B6 mice were purchased from Taconic (Hudson, NY) or bred in a barrier (SPF) facility at
GRU. IDO1-KO mice, CD11cDTR, OT1 and OT2 TCR transgenic mice were described previ-
ously [15, 22].
Influenza (IAV) infection
IAV A/PR/8/34 (PR8) propagated in embryonated chicken eggs was kindly provided by Ralph
Tripp (University of Georgia Athens, GA). Mice were infected with a non-lethal IAV dose
(30pfu, 30% of LD50) as described [5].
MuLV (LP-BM5) infection
SC1/G6 cells infected with MuLV (LP-BM5) were obtained from the NIH AIDS Reagent Pro-
gram, Division of AIDS, NIAID, NIH [8]. SC1 and XC cells were kind gifts fromWilliam
Green (Dartmouth). 400ul of SC1/G6 culture supernatant were injected (i/v) to infect mice.
Ecotropic (Eco) retrovirus titers in supernatants were determined by XC plaque assay [35]. 1-
5x104 pfu Eco retrovirus was injected per mouse [9]. Adoptive transfer of splenocytes from
MuLV-infected mice was accomplished by exposing naïve IDO1-KO recipients to sub-lethal
radiation (3.5Gy) to create space in hematologic niches.
Mechanical nociception test
Mechanical nociception was assessed using von Frey filaments (North Coast Medical Inc, Gil-
roy, CA) to determine paw withdrawal threshold (PWT) as described [36, 37]. In brief, mice
were stimulated on both hind paws using a series of von Frey filaments ranging in force from
0.008g to 2g, starting with the 0.008g filament. Positive responses were scored as paw with-
drawal occurring two or more times in response to ten successive stimulations. In the event of
negative responses, mice were then stimulated with monofilaments of stepwise increasing
force. The monofilament that first evoked a positive response was designated the threshold (in
grams) and no further monofilaments were applied.
Flow cytometry
Cells were analyzed on a LSRII flow cytometer (Becton-Dickinson). Data were analyzed using
FACS DIVA (BD Bioscience) or FlowJo (Tree Star, Ashland, OR) software. An Aria flow sorter
(Becton-Dickinson) was used for sort spleen cells fromMuLV-infected mice under BSL2 con-
ditions. Spleen cells fromMuLV-infected mice were stained with PE-conjugated rat anti-
mouse CD19 (clone 1D3, BD Biosciences) and APC or PECy7-conjugated hamster anti-mouse
CD11c (clone N418, eBioScience). Cells were sorted into chilled polypropylene collection tubes
(RPMI, 10% FCS) for culture or resuspended (RPMI, 5% FCS) and cell lysis solution was
added (Omega Bio-Tek, Norcross, GA) to prepare RNA for analysis. In vivo Ethynyl deoxyluri-
dine (EdU) labeling and staining were performed using Click-iT Plus EdU flow cytometry
assay kits (Life Technologies) following manufacturer’s instructions with minor modifications.
Briefly, 1mg of EdU was injected into each mouse (i/p) and tissues are harvested four hours
later. Spleen cells were surface stained with antibodies then fixed and permeablized followed by
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incubation with fluorophore conjugated azide. Cells are then washed and analyzed on a BD
FACS LSRII flow cytometer.
IDO inhibitor and IDO activity assays
1-methyl-[D]-tryptophan (D-1MT, Indoximod) was kindly provided by NewLink Genetics
Inc. D-1MT was administered in sweetened drinking water (2mg/ml) as described [15]. IDO
enzyme activity was measured by assessing Kyn produced by cell-free tissue homogenates or
present in cell cultures using HPLC as described [5].
RT-PCR assays
RNA was purified using HP total RNA kits (Omega Bio-Tek, Norcross, GA), reverse-tran-
scribed using a random hexamer cDNA RT kit (Clontech, Mountain View, CA), and quantita-
tive RT-PCR was performed using an iQ5 or CFX system with SsoFast EvaGreen supermix
(Bio-Rad, Hercules, CA). Primers for murine β-actin were (forward) 50-TACGGATGTCAAC
GTCACAC-30 and (reverse) 5-AAGAGCTATGAGCTGCCTGA-30. Validated primers for
murine IDO1 were purchased (realtimeprimers.com). Relative expression of GAGEco and
GAGDef were evaluated as described [38]. Threshold cycle (Ct) values were set in the early lin-
ear amplification phase; relative expression was calculated as 2Ct(β-actin) − Ct(target gene).
Statistical analyses
Time courses of mechanical nociception (PWT) were analyzed by two-way ANOVA with mul-
tiple comparisons. Unpaired Student t tests were used to analyze data generated in all other
experiments. Two-tailed p values<0.05 were considered significant. GraphPad Prism was used
to perform all data analyses.
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. All protocols were
reviewed and approved by the Animal Care and Use Committee at the Georgia Regents Uni-
versity (AUP#2011–0330).
IDO1 gene information
Gene ID: 15930; Ensembl: ENSMUSG00000031551; Vega: OTTMUSG00000020648
Supporting Information
S1 Fig. Increased pain sensitivity and inflammatory responses in MuLV-infected mice. A,
B. Pain thresholds (PWT) were measured at 56dpi and 70dpi in MuLV-infected mice bred in
the local facility (A) or purchased from Taconic (B). Slight decreases in pain thresholds in
IDO1-KO mice were not statistically significant, relative to pain thresholds in naïve mice. Sta-
tistical analyses were performed using Student’s t test (A) or 2-way ANOVA (B);  p<0.001,
 p<0.0001. Data were pooled from 2 or more experiments, except data in panel B was from
one experiment. C-F. Inflammatory cytokine levels in serum and spleen were measured by
multiplex analyses (Luminex) in naïve and MuLV-infected (42dpi) B6 and IDO1-KO mice;
IFNγ (C), IL6 (D), TNFα (E) and IP10 (F). Statistical analyses revealed no significant differ-
ences in cytokine levels in samples fromMuLV-infected mice WT and IDO1-KO mice (Stu-
dent’s t test).
(TIF)
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S2 Fig. IDO expression in tissues fromMuLV-infected mice. Tissues from naïve or MuLV-
infected WTmice were analyzed to detect IDO enzyme activity in spleen (A, 56dpi) or IDO1
gene transcripts (qPCR) in spinal cord (B, 30dpi). Statistical analyses were performed using
Student’s t test;  p<0.01. Experiments were performed once.
(TIF)
S3 Fig. Proliferation of splenic DCs in MuLV-infected mice is driven by interactions with
CD4 T cells.MuLV-infected WT mice (28dpi) were treated with anti-CD4 mAbs on two suc-
cessive days (400μg/mouse, i/v) and were injected with the dye EdU (400 μg/mouse, i/v) 3 days
after the second mAb treatment. After 16 hours, spleen samples were stained with CD11c and
CD19 mAbs and analyzed by flow cytometry to detect proliferating DCs marked with EdU.
Statistical analyses were performed using Student’s t test;  p<0.0001. Data were pooled
from 2 experiments.
(TIF)
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